Novan, Inc. (NOVN)

1,1800 +0,0300 (+2,61%) Al 03:18PM EDT. Mercato aperto.

Novan, Inc.

4020 Stirrup Creek Drive
Suite 110
Durham, NC 27703
United States
919 485 8080
https://www.novan.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 29

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Ms. Paula Brown Stafford M.P.H.	Pres, CEO & Chairwoman	1,01M	N/D	1965
Mr. John M. Gay CPA	CFO & Corp. Sec.	482,26k	N/D	1976
Mr. Brian M. Johnson	Chief Commercial Officer	443k	N/D	1966
Mr. John A. Donofrio Jr.	Exec. VP, COO & Pres of EPI Health	N/D	N/D	1967
Mr. Andrew J. Novak	VP of Accounting & Bus. Operations and Chief Accounting Officer	N/D	N/D	N/D
Dr. Carri Geer Ph.D.	Sr. VP & CTO	N/D	N/D	N/D
Mr. Cole Ikkala	Director of Investor Relations, Communications & Bus. Devel.	N/D	N/D	N/D
Mr. Stanley Hollenbach BS, J.D.	Sr. VP of R&D	N/D	N/D	N/D
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.	Chief Medical Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Novan, Inc., a medical dermatology company, focuses on researching, developing, and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Governance aziendale

L'ISS Governance QualityScore di Novan, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.